 Kintara Therapeutics, Inc. NASDAQ:KTRA has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research GCAR registrational Phase 23 clinical trial for glioblastoma multiforme GBM has been activated in 15 US sites as of May 14, 2021. The trial, titled GBM AGILE Glioblastoma Adaptive Global Innovative Learning Environment, is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. 